(Q43631043)

25 November 2017

0 references

Oncolytic viruses: focusing on the tumor microenvironment (English)

1 reference

25 November 2017

1 reference

C R de Vries

1

1 reference

25 November 2017

H L Kaufman

series ordinal

2

1 reference

25 November 2017

E C Lattime

series ordinal

3

1 reference

25 November 2017

language of work or name

1 reference

27 February 2015

1 reference

25 November 2017

1 reference

25 November 2017

22

1 reference

25 November 2017

4

1 reference

25 November 2017

169-171

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2015.11

25 November 2017

0 references

cites work

Going viral with cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

The consensus coding sequences of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Measles virus causes immunogenic cell death in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Poxviral-based vaccine elicits immunologic responses in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.11

Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma

21 January 2018

1 reference

12 December 2020

Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells

1 reference

12 December 2020

Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site

1 reference

12 December 2020

Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses

1 reference

12 December 2020

Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen

1 reference

12 December 2020

A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment

1 reference

12 December 2020

Identifiers

DOI

10.1038/CGT.2015.11

1 reference

Dimensions Publication ID

25 November 2017

0 references

1 reference